Alan Pollack, M.D., Ph.D.
- Fax: 305-689-4451
- Radiation Oncology
I specialize clinically in: GU Malignancies (Prostate, Bladder and Testicular cancers) and Sarcomas.
- American Board of Radiology-Radiation Oncology
- Professor and Chairman of Radiation Oncology
My research interests are: Radiation fractionation, gene and small molecule therapy to enhance the response of prostate tumor cells to radiation and/or androgen deprivation, and biomarkers to predict response and determine the most appropriate treatment.
My clinical research has focused on prostate and bladder cancers. I am the principal Investigator on a large Phase III prostate cancer randomized trial through the Radiation Therapy Oncology Group (RTOG protocol 0534). This is a post-prostatectomy trial testing the benefits of treating the pelvic lymph nodes and the concurrent use of androgen deprivation with radiation. I am the co-PI on a national bladder cancer trial through the RTOG testing the use of Herceptin in her-2 expressing muscle-invasive bladder tumors (RTOG protocol 0524). Also, I am developing a new trial at the University of Miami designed to target areas of bulky tumor in men with prostate cancer using dynamic contrast enhanced MR imaging.
My laboratory research has involved primarily the exploration of potential biomarkers and the addition of targeted therapy (gene and small molecule) to radiotherapy and androgen deprivation therapy. Through the RTOG translational research program a number of potential biomarkers for prostate cancer have been investigated using immunohistochemical staining and analysis (image and manual quantification of biomarker expression). The targeted therapy studies have included preclinical investigations of a number of agents, such as adenoviral-p53, adenoviral-E2F1, antisense-MDM2, antisense-PKA and antisense-bcl-2 in mouse models. The effects of these agents on prostate cancer cell survival in vitro and tumor growth in vivo are being examined.
- For more information about Dr. Pollack see CV